tiprankstipranks
Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
Press Releases

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12th-14th, 2022.

H.C. Wainwright Global Investment Conference fireside chat details:

Date: Thursday, September 14th, 2022
   
Time: 4:00 pm Eastern Time
   
Webcast: The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit www.immunovant.com

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles